In Tomas Philipson's latest Forbes.com op-ed, he examines the challenges of value assessment in the U.S. healthcare system and describes a decentralized approach to assessing value that better suits the U.S. context. Using IVI as an example, Philipson outlines several key criteria that a decentralized value assessment approach should meet in order to effectively link [...]
In a recent post on the IVI-sponsored Health Affairs blog series, David Tawes and Marta Wosinka examine consequences of the disconnection between market prices and reimbursement, specifically in that Medicare still uses 2003 average wholesale prices (AWPs) for some drugs. Tawes and Wosinka point out that, in the case of drugs where the actual costs [...]
In the wake of the election, Darius Lakdawalla (Executive Director of IVI) and Dana Goldman provide a "policy prescription list" to enable lower prices and improved patient access without discouraging medical innovation in a new commentary for STAT News. Read the full article here.
Alison Sexton Ward, Mark Linthicum, Michelle Drozd, Alison Silverstein, and Joe Vandigo identify key legal and regulatory barriers in the creation of value-based contracts for drugs in their recent addition to the IVI-sponsored Health Affairs blog series. Based on two-part, in-depth interviews with a group of five stakeholders regarding their experience with value-based agreements, the authors identify [...]
In a recent post on the IVI-sponsored Health Affairs blog series, Darius Lakdawalla, Executive Director of IVI, and Peter Neumann discuss the use of explicit budget impact criteria in value assessment. Lakdawalla and Neumann write that budgetary concerns are understandable, given that healthcare decision makers are faced with limited resources. Linking short-term budget criteria to assessments of [...]
Dana Goldman addresses the firestorm created by Mylan's dramatic price hikes for their EpiPen in a new commentary published in STAT News. Read the full article here.
IVI Executive Director, Darius Lakdawalla, is featured in the AP's Big Story, discussing the need for a more rational drug pricing model. Read the full article here.
In a commentary for Modern Healthcare, Dana Goldman describes how access and pricing for generic drugs could be improved by taking a lesson from vaccine policy. Read the full article here.
In Tomas Philipson's latest Forbes.com op-ed, he and co-author Anupam Jena suggest it is time to stop scratching the surface when it comes to value in healthcare. Read the full article here.
While the rest of the health care system is moving toward paying for value, payments for drugs largely continue to be stuck in a 20th century construct that focuses on price, regardless of the health outcomes of each patient. This lack of payment innovation is particularly damaging in an era where on the horizon new [...]
